<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PRINCIPAL FINDINGS: In mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (JeKo-1), Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Raji), and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (697) cell lines, the 48-hr IC(50) (50% growth inhibitory concentration) of AR-42 is 0.61 microM or less </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) patient cells, the 48-hr LC(50) (concentration lethal to 50%) of AR-42 is 0.76 microM </plain></SENT>
<SENT sid="4" pm="."><plain>AR-42 produces dose- and time-dependent acetylation both of <z:chebi fb="0" ids="15358">histones</z:chebi> and tubulin, and induces caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> that is not reduced in the presence of stromal cells </plain></SENT>
<SENT sid="5" pm="."><plain>AR-42 also sensitizes CLL cells to TNF-Related <z:mpath ids='MPATH_3'>Apoptosis</z:mpath> Inducing Ligand (TRAIL), potentially through reduction of c-FLIP </plain></SENT>
<SENT sid="6" pm="."><plain>AR-42 significantly <z:mp ids='MP_0000221'>reduced leukocyte counts</z:mp> and/or prolonged survival in three separate mouse models of B-cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> without evidence of toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/SIGNIFICANCE: Together, these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses </plain></SENT>
<SENT sid="8" pm="."><plain>These results strongly support upcoming phase I testing of AR-42 in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>